|
B2Bpharm 2/11/02 10:35 AM Page 2
B R O A D V I S I O N
BroadVision Business-to-Business Solutions for the Pharmaceutical Industry:Accelerating Time to Market for New Drugs
WHITE P A P E RB2Bpharm 2/11/02 10:35 AM Page 3
Contents
3 Executive Summary
3 New Opportunities
4 New Challenges
5 A Changing Industry
6 The Need for Improved Collaboration
7 Streamlined Information Exchange Speeds Time to Market
8 Safeguarding Intellectual Property
8 Improved Quality and Reliability
9 Faster Regulatory Compliance
9 BroadVision's Unique Added Value
9 ConclusionB2Bpharm 2/11/02 10:35 AM Page 4
BB RR OO AA DD VV II SS II OO NN
Executive SummaryThe pharmaceutical industry is in the midst of a revolution. On the one hand, growing demand byan aging population in the United States, Western Europe and Japan wishing to maintain a highquality of life, and by the managed care industry wishing to cut costs, is increasing demand fornew drug treatments. On the other hand, new technologies for discovering disease targets anddrugs to alleviate these conditions have greatly increased the number of potential candidates fornew drug treatments in the pipeline. But with these opportunities have come new challenges.The sheer volume and complexity of these leads is straining the ability of pharmaceutical com-panies to follow up. At the same time, reduced patent-exclusivity periods mean that pharmaceu-tical companies are under increased financial pressure to develop more drugs more quickly tomaintain a competitive advantage.
To cope with these challenges, the pharmaceutical industry is undergoing a tremendous trans-formation. Pharmaceutical companies are merging to gain a breadth of expertise and are refin-ing their focus to a few disease states. They're also increasingly outsourcing clinical trials andmolecule synthesis to independent service providers to help follow up drug candidate leads.This trend toward outsourcing has created the need for ways to improve collaboration with part-ners. ŽBroadVision technology can help pharmaceutical companies ensure effective collaboration withpartners. By streamlining the exchange of critical information about drugs, clinical trials andmolecule synthesis processes with partners, BroadVision collaboration capabilities allow phar-maceutical companies to:
. Eliminate dead ends while at the same time safeguarding intellectual property. Improve quality and reliability of research results by allowing pharmaceutical companies to moni-tor more closely how partners are performing their work. Speed the new drug approval process-both within the United States and worldwide-by help-ing pharmaceutical companies to provide regulatory agencies with more complete information ina more timely fashion
Using these BroadVision capabilities, pharmaceutical companies can take advantage of thefirst-mover and first-to-critical-mass advantages necessary to thrive in today's competitive andfast-moving environment.
New OpportunitiesThe $315 billion pharmaceuticals industry has grown almost 10 percent year-over-year for the pastdecade. Forecasts predict that growth is likely to continue at this rate for the foreseeable future.This growth has been fueled by an increase in both demand for and supply of new drug products.
Demand comes from aging populations in North America, Western Europe and Japan that wish tomaintain their quality of life. The managed care organizations that treat these patients also realizethat preventative pharmaceutical therapy is significantly less expensive than hospitalization orinvasive surgery.
At the same time, new drug discovery methods are allowing pharmaceutical companies to meet
3B2Bpharm 2/11/02 10:35 AM Page 5
BroadVision Business-to-Business Solutions for the Pharmaceutical Industry:Accelerating Time to Market for New Drugs
this demand with an increasing supply of new products. The Human Genome Project has alreadyidentified disease targets for new therapies, including targets for breast cancer, colon cancer,Crohn's disease, Alzheimer's and others. To alleviate these diseases, new combinatorial chem-istry and high throughput screening (HTS) processes are allowing researchers to create drugcandidate libraries with tens of thousands of molecules, then to identify a lead drug series inmonths instead of years. As a resu... [download for more]
|
